Nebratamig Biosimilar – Anti-Tumor necrosis factor receptor superfamily member 9 mAb – Research Grade from ProteoGenix; catalogue PX-TA1983; research
Know who made it. See the evidence. Buy through one marketplace.
Introduction to Nebratamig Biosimilar – Anti-Tumor Necrosis Factor Receptor Superfamily Member 9 mAb Nebratamig Biosimilar is a novel therapeutic antibody that targets the tumor necrosis factor receptor superfamily member 9 (TNFRSF9), also known as CD137. This biosimilar is designed to mimic the activity of the original antibody, with the potential to treat various inflammatory and autoimmune diseases. In this article, we will explore the structure, activity, and potential applications of Nebratamig Biosimilar.
Nebratamig Biosimilar is a monoclonal antibody (mAb) that is produced in a laboratory using recombinant DNA technology. It is a fully humanized antibody, meaning that it is derived from human cells and is less likely to cause an immune response in patients. The antibody has a molecular weight of approximately 150 kDa and is composed of two identical heavy chains and two identical light chains. It also contains a variable region, which is responsible for binding to the target TNFRSF9.
TNFRSF9 is a cell surface receptor that is expressed on various immune cells, including T cells, B cells, and natural killer cells. This receptor plays a critical role in regulating immune responses and is involved in the development of autoimmune diseases. Nebratamig Biosimilar binds to TNFRSF9 and blocks its activity, thereby inhibiting the production of pro-inflammatory cytokines and reducing the activation of immune cells.
Additionally, Nebratamig Biosimilar has been shown to induce the death of TNFRSF9-expressing cells through a process called antibody-dependent cell-mediated cytotoxicity (ADCC). This mechanism of action further contributes to the anti-inflammatory effects of Nebratamig Biosimilar.
Nebratamig Biosimilar has shown promising results in preclinical studies for the treatment of various autoimmune and inflammatory diseases, including rheumatoid arthritis, psoriasis, and inflammatory bowel disease. It has also been investigated as a potential therapy for solid tumors, as TNFRSF9 is known to be overexpressed on the surface of cancer cells.
In addition to its therapeutic potential, Nebratamig Biosimilar is also being used as a research tool to study the role of TNFRSF9 in various diseases. It has been used in in vitro and in vivo experiments to elucidate the signaling pathways and mechanisms of action of TNFRSF9.
Nebratamig Biosimilar is a promising therapeutic antibody that targets TNFRSF9, a key regulator of immune responses. Its unique structure and mechanism of action make it a potential treatment for various inflammatory and autoimmune diseases. Furthermore, its use as a research tool has provided valuable insights into the role of TNFRSF9 in disease pathogenesis. As clinical trials continue to evaluate its safety and efficacy, Nebratamig Biosimilar has the potential to be a valuable addition to the arsenal of biologic therapies available for patients.
ProteoGenix catalogue number PX-TA1983. For research use only.
Target: Nebratamig Biosimilar – Anti-Tumor necrosis factor receptor superfamily member 9 mAb – Research Grade; Clonality: Monoclonal Antibody; Expression system: XtenCHO; Buffer: 0.01M PBS, pH 7.4; Applications: ELISA, WB.
Available configurations: 50ug, 100ug, 1mg.
Fully tested in-house by ABMIUM, or supported by an advanced validation report from a partner reviewed by ABMIUM. Highest confidence. Non-conformities fully supported under the ABMIUM Product Promise.
Quality verified. Independent collaborator or expected-performance data available. Product meets ABMIUM quality standards.
Expected to work based on structural and biochemical data. Not yet directly tested by ABMIUM or a collaborator. No non-conformity support for this combination.
Not recommended for this application or species/sample combination. This may indicate either evidence of unsuitability or that the combination has not been tested and therefore cannot currently be recommended.
Evidence status by application and model.
| Target | WB | IHC-P | IHC-Fr | IF/ICC | Flow Cyt | IP | ChIP | ELISA |
|---|---|---|---|---|---|---|---|---|
| Nebratamig Biosimilar – Anti-Tumor necrosis factor receptor superfamily member 9 mAb – Research Grade |
This product is manufactured by ProteoGenix and sold through ABMIUM without relabelling.
ABMIUM supports global orders. Availability, shipping requirements and applicable import arrangements are confirmed before fulfilment where required.
Yes. Send your target, sample, application and experimental conditions through ABMIUM MATCH or technical support.
Unless the listing expressly states otherwise, ABMIUM products are supplied for research use only and are not for diagnostic or therapeutic use.
